Laser: gastrointestinal applications.

R A Kozarek

Home/Archive/PubMed

PubMed · 6608258

Laser: gastrointestinal applications.

R A Kozarek

View original source ↗Export metadata ↓

Abstract

Although still considered an investigational medical device, and therefore restricted to use in clinical trials, the Nd:YAG laser has become increasingly available in the United States. The laser has been successfully used in the treatment of acute and chronic gastrointestinal bleeding, and for the palliation or ablation of intestinal tract neoplasms. Ongoing trials are needed to determine the cost-effectiveness and side-effect liability as compared to more conventional medical and surgical therapy.

Explore related subjects

Gastrointestinal Diseases Gastrointestinal Hemorrhage Gastrointestinal Neoplasms Humans Laser Therapy Lasers Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

R A Kozarek. 1984. Laser: gastrointestinal applications.. https://pubmed.ncbi.nlm.nih.gov/6608258/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

[Symptoms involving the gastrointestinal tract].

Symptoms involving the gastrointestinal tract are very common in patients who require palliative treatment. They can be caused by the patient's underlying (malignant) disease or by the treatment of this disease. Nausea and vomiting as well as constipation are of the utmost importance in this context due both to their frequency as well as their complex consequences. A careful evaluation of the patient's history combined with a few diagnostic procedures will help to provide a treatment which is orientated on pathophysiology.

Gastrointestinal Diseases↗

PubMed2006

Thymidine phosphorylase gene mutations cause mitochondrial neurogastrointestinal encephalomyopathy (MNGIE).

Explore the source record for details and available documents.

Gastrointestinal Diseases↗

PubMed2006

Serotonergic receptors in therapeutic approaches to gastrointestinal disorders.

Most of the cloned serotonin (5-HT) receptor subtypes are present on enteric neurons that control gastrointestinal function. Because of the wide distribution of 5-HT receptor subtypes in the gut, the precise actions of currently marketed drugs are unclear. Furthermore, efficacy of these drugs varies between individuals. Two recent advances provide important potential explanations for this phenomenon: polymorphisms have recently been discovered in the gene for the key enzyme in neural 5-HT production, and physiologically relevant 5-HT(4) receptor splice variants have been shown to be differentially located across intestinal regions. Functional 5-HT(7) receptors have recently been demonstrated in the gut and, together with the 5-HT(1A) receptor, offer new therapeutic options. In addition, recently suggested identities for the elusive 5-HT(1P) receptor could result in other, more effective therapeutic targets.

Gastrointestinal Diseases↗